Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Calidi BiotherapeuticsCLDI -9.50%12 Revenue per Share is $0.00 as of Mar. 2026. GuruFocus rates CLDI with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 769 Biotechnology companies, Calidi Biotherapeutics ranks worse than 130038.88% on this metric.
Calidi Biotherapeutics's revenue per share for the
three
months ended in Mar. 2026 was $0.00.
Calidi Biotherapeutics's revenue per share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Calidi Biotherapeutics's Revenue per Share or its related term are showing as below:
CLDI's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3 * Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Calidi Biotherapeutics Revenue per Share Related Terms
Calidi Biotherapeutics Revenue per Share Historical Data
* Premium members only.
The historical data trend for Calidi Biotherapeutics's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLDI vs BBLG, CDT, BPTH: Revenue per Share Comparison
For the Biotechnology subindustry, Calidi Biotherapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Calidi Biotherapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Calidi Biotherapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Calidi Biotherapeutics's PS Ratio falls into.
Calidi Biotherapeutics Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Calidi Biotherapeutics's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Calidi Biotherapeutics (CLDI) has a Revenue per Share of $0.00 as of Mar. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Calidi Biotherapeutics and its competitors. According to the industry distribution chart, Calidi Biotherapeutics ranks #999999 out of 769 companies in the Biotechnology industry.
Is Calidi Biotherapeutics' Revenue per Share too high?
Calidi Biotherapeutics' current Revenue per Share is $0.00. Based on the distribution chart, Calidi Biotherapeutics ranks #999999 out of 769 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Calidi Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Calidi Biotherapeutics' Revenue per Share compare to BBLG and CDT?
According to the Biotechnology industry distribution chart, Calidi Biotherapeutics ranks #999999 out of 769 companies for Revenue per Share. This places Calidi Biotherapeutics in the lower half of its industry. The industry median Revenue per Share is 3.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Biotechnology company?
The median Revenue per Share among Biotechnology companies is 3.00, based on 769 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Calidi Biotherapeutics and its competitors. For the Biotechnology industry, the median Revenue per Share is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Calidi Biotherapeutics's current Revenue per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Calidi Biotherapeutics stock overvalued right now?
Calidi Biotherapeutics (CLDI) has a current Revenue per Share of $0.00. The current Revenue per Share is $0.00. Calidi Biotherapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Calidi Biotherapeutics (CLDI), the current Revenue per Share is $0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
12GF Score
Get the complete analysis for CLDI
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLDI has been successfully added to your 
